Trial Summary
What is the purpose of this trial?This trial uses a special radioactive drug and a heart scan to help identify Lewy Body Disease in people with certain neurological symptoms. The scan checks how well the heart absorbs the drug to find early signs of this brain disorder.
Eligibility Criteria
This trial is for individuals with certain neurological disorders like Lewy Body Disease, Parkinson's, or dementia. Participants need a caregiver present at least 20 hours per week and must have stable medication use without severe medical conditions that could interfere with the study.Inclusion Criteria
I have a caregiver with me for at least 4 hours a day, 5 days a week.
You have been diagnosed with one of the specific medical conditions using well-known criteria.
Your STMS score is higher than 10.
+13 more
Exclusion Criteria
You are allergic to the radioligand or iodine.
I am willing and able to follow all study-related procedures.
Any other medical disorder considered by the study physicians as inappropriate for enrollment in this protocol
+10 more
Participant Groups
The trial tests a radioactive drug called 123I-MIBG and its ability to diagnose Lewy Body Disease through myocardial MIBG scintigraphy scans. It aims to improve disease prediction by correlating scan results with other clinical data.
1Treatment groups
Experimental Treatment
Group I: Myocardial 123I-MIBG scintigraphy imagingExperimental Treatment2 Interventions
Subjects with with normal neurologic functioning, REM sleep without atonia, RBD, parkinsonism, cognitive impairment, or some combination of these will undergo myocardial 123I-MIBG scintigraphy imaging
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mayo Clinic in RochesterRochester, MN
Loading ...
Who Is Running the Clinical Trial?
Mayo ClinicLead Sponsor